Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Rosell R"'
Autor:
Dafni, U, Soo, R A, Peters, S, Tsourti, Z, Zygoura, P, Vervita, K, Han, J-Y, De Castro, J, Coate, L, Früh, M, Hashemi, S M S, Nadal, E, Carcereny, E, Sala, M A, Bernabé, R, Provencio, M, Cuffe, S, Roschitzki-Voser, H, Ruepp, B, Rosell, R, Stahel, R A
Publikováno v:
Dafni, U; Soo, R A; Peters, S; Tsourti, Z; Zygoura, P; Vervita, K; Han, J-Y; De Castro, J; Coate, L; Früh, M; Hashemi, S M S; Nadal, E; Carcereny, E; Sala, M A; Bernabé, R; Provencio, M; Cuffe, S; Roschitzki-Voser, H; Ruepp, B; Rosell, R; ... (2022). Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis. ESMO open, 7(3), p. 100507. Elsevier 10.1016/j.esmoop.2022.100507
Dafni, U, Soo, R A, Peters, S, Tsourti, Z, Zygoura, P, Vervita, K, Han, J Y, de Castro, J, Coate, L, Früh, M, Hashemi, S M S, Nadal, E, Carcereny, E, Sala, M A, Bernabé, R, Provencio, M, Cuffe, S, Roschitzki-Voser, H, Ruepp, B, Rosell, R & Stahel, R A 2022, ' Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC—a systematic review and meta-analysis ', ESMO OPEN, vol. 7, no. 3, 100507 . https://doi.org/10.1016/j.esmoop.2022.100507
ESMO OPEN, 7(3):100507. BMJ Publishing Group
Dafni, U, Soo, R A, Peters, S, Tsourti, Z, Zygoura, P, Vervita, K, Han, J Y, de Castro, J, Coate, L, Früh, M, Hashemi, S M S, Nadal, E, Carcereny, E, Sala, M A, Bernabé, R, Provencio, M, Cuffe, S, Roschitzki-Voser, H, Ruepp, B, Rosell, R & Stahel, R A 2022, ' Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC—a systematic review and meta-analysis ', ESMO OPEN, vol. 7, no. 3, 100507 . https://doi.org/10.1016/j.esmoop.2022.100507
ESMO OPEN, 7(3):100507. BMJ Publishing Group
BACKGROUND The ETOP 10-16 BOOSTER trial failed to demonstrate a progression-free survival (PFS) benefit for adding bevacizumab to osimertinib in second line. An exploratory subgroup analysis, however, suggested a PFS benefit of the combination in pat
Autor:
Jantus-Lewintre, E, Sureda, BM, Larriba, JLG, Rodriguez-Abreu, D, Juan, O, Blasco, A, Domine, M, Pulla, MP, Garde, J, Alvarez, R, Maestu, I, de Carrion, RP, Artal, A, Rolfo, C, de Castro, J, Guillot, M, Oramas, J, de las Penas, R, Ferrera, L, Martinez, N, Serra, O, Rosell, R, Camps, C, Grp Espanol Canc Pulmon GECP
Publikováno v:
Frontiers in Oncology
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Dipòsit Digital de la UB
Universidad de Barcelona
r-FIHGUV. Repositorio Institucional de Producción Científica de la Fundación de Investigación del Hospital General de Valencia
Zaguán. Repositorio Digital de la Universidad de Zaragoza
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
r-FISABIO. Repositorio Institucional de Producción Científica
Frontiers in Oncology, Vol 11 (2021)
r-CIPF. Repositorio Institucional Producción Científica del Centro de Investigación Principe Felipe (CIPF)
Universitat Rovira i virgili (URV)
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Dipòsit Digital de la UB
Universidad de Barcelona
r-FIHGUV. Repositorio Institucional de Producción Científica de la Fundación de Investigación del Hospital General de Valencia
Zaguán. Repositorio Digital de la Universidad de Zaragoza
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
r-FISABIO. Repositorio Institucional de Producción Científica
Frontiers in Oncology, Vol 11 (2021)
r-CIPF. Repositorio Institucional Producción Científica del Centro de Investigación Principe Felipe (CIPF)
Universitat Rovira i virgili (URV)
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
[EN] Finding angiogenic prognostic markers in advanced non-small-cell lung cancer is still an unmet medical need. We explored a set of genetic variants in the VEGF-pathway as potential biomarkers to predict clinical outcomes of patients with non-smal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00dbcd0ee9066d25075d9251920eaf96
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=14765
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=14765
Autor:
Wei, J, Costa, C, Shen, J, Yu, L, Sanchez, J J, Qian, X, Sun, X, Zou, Z, Gimenez-Capitan, A, Yue, G, Guan, W, Rosell, R, Liu, B, Universitat Autònoma de Barcelona
Publikováno v:
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
British Journal of Cancer
Recercat. Dipósit de la Recerca de Catalunya
instname
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
British Journal of Cancer
Recercat. Dipósit de la Recerca de Catalunya
instname
Background: Breast cancer susceptibility gene 1 (BRCA1) expression differentially affects outcome to platinum- and taxane-based chemotherapy. Mediator of DNA damage checkpoint protein 1 (MDC1), p53-binding protein 1 (53BP1), multiple myeloma SET doma
Autor:
Scagliotti, Giorgio Vittorio, Kortsik, C, Dark, Gg, Price, A, Manegold, C, Rosell, R, Obrien, M, Peterson, Pm, Castellano, D, Selvaggi, G, Novello, Silvia, Blatter, J, Kayilitare, L, Crin, L, PAZ ARES, L.
Publikováno v:
Clinical Cancer Research. 11:690-696
Purpose: To determine efficacy and toxicity of two pemetrexed-based regimens in chemonaive patients with locally advanced or metastatic non–small cell lung cancer. Experimental Design: Patients were randomly assigned to receive pemetrexed 500 mg/m2
Autor:
Rosell, R, Carcereny, E, Gervais, R, Vergnenegre, A, Massuti, B, Felip, E, Palmero, R, Garcia Gomez, R, Pallares, C, Sanchez, Jm, Porta, R, Cobo, M, Garrido, P, Longo, F, Moran, T, Insa, A, De Marinis, F, Corre, R, Bover, I, Illiano, A, Dansin, E, de Castro, J, Milella, M, Reguart, N, Altavilla, Giuseppe, Jimenez, U, Provencio, M, Moreno, Ma, Terrasa, J, Muñoz Langa, J, Valdivia, J, Isla, D, Domine, M, Molinier, O, Mazieres, J, Baize, N, Garcia Campelo, R, Robinet, G, Rodriguez Abreu, D, Lopez Vivanco, G, Gebbia, V, Ferrera Delgado, L, Bombaron, P, Bernabe, R, Bearz, A, Artal, A, Cortesi, E, Rolfo, C, Sanchez Ronco, M, Drozdowskyj, A, Queralt, C, de Aguirre, I, Ramirez, Jl, Sanchez, Jj, Molina, Ma, Taron, M, Paz Ares, L, on behalf of the Spanish Lung Cancer Group in collaboration with the Groupe Français de Pneumo Cancérologie, the Associazione Italiana Oncologia Toracica
Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations. We aimed to assess the safety and e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1b9a71369a087096af8e0a8a8e4b4d6
http://hdl.handle.net/11570/2538232
http://hdl.handle.net/11570/2538232
Autor:
Rosell, R., Botero, M. L., Gonzales Cao, M., Margeli, M., Barnadas, A., Cusido, M. T., Fabregas, R., Costa, C., Gimenéz Capitan, A., Santarpia, Mariacarmela, Benlloch, S.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9db759e275532212af348c40155be0c
http://hdl.handle.net/11570/3023176
http://hdl.handle.net/11570/3023176
Autor:
Pignon, Jp, Tribodet, H, Scagliotti, Giorgio Vittorio, Douillard, Jy, Shepherd, Fa, Stephens, Rj, Dunant, A, Torri, V, Rosell, R, Seymour, L, Spiro, Sg, Rolland, E, Fossati, R, Aubert, D, Ding, K, Waller, D, Le Chevalier, T, LACE Collaborative Group
Purpose Several recent trials have shown a significant overall survival (OS) benefit from postoperative cisplatin-based chemotherapy in patients with non–small-cell lung cancer (NSCLC). The aim of the Lung Adjuvant Cisplatin Evaluation was to ident
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bcc2dc60ad9bafc025064c6a0891b53
http://hdl.handle.net/2318/48055
http://hdl.handle.net/2318/48055
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Salamanca Oscar, López-Alonso Antonio, Sanz Juan-Luis, Hernando Teresa, Rico-Villademoros Fernando, Camps Carlos, Rosell Rafael
Publikováno v:
BMC Medical Research Methodology, Vol 4, Iss 1, p 6 (2004)
Abstract Background The purpose of this study was to determine the standard tasks performed by clinical research coordinators (CRCs) in oncology clinical trials. Methods Forty-one CRCs were anonymously surveyed, using a four-page self-administered qu
Externí odkaz:
https://doaj.org/article/95af236424e24863b7a9112bfc824c44
Autor:
Umberto Malapelle, Daniel Stieber, Elena Vigliar, Michel Bihl, Giancarlo Troncone, Reinhard Büttner, David H. Hwang, Birgit Weynand, Matteo Fassan, Miguel Angel Molina-Vila, Sonika Saddar, Fernando Schmitt, Francesco Pepe, Rajyalakshmi Luthra, Philippe Vielh, Massimo Barberis, Alessandra Rappa, Lukas Bubendorf, Yuri E. Nikiforov, Cristiana Lupi, Qi Zheng, Rafael Rosell, Catherine I. Dumur, Giovanni Tallini, Marina N. Nikiforova, Massimo Bongiovanni, Sinchita Roy-Chowdhuri, Lynette M. Sholl, Dario Bruzzese, Claudio Bellevicine, Gabriella Fontanini, Gianluca Roma, Carlos E. de Andrea, Massimo Rugge, Clara Mayo-de-las-Casas, Sabine Merkelbach-Bruse, Dario de Biase, Spasenija Savic, Maria D. Lozano, Bettina Bisig, Pasquale Pisapia, Sara Vander Borght
Publikováno v:
Cancer cytopathology. 127(5)
Background: Artificial genomic reference standards in a cytocentrifuge/cytospin format with well-annotated genomic data are useful for validating next-generation sequencing (NGS) on routine cytopreparations. Here, reference standards were optimized t